TOP-M119
Androgenetic Alopecia
Phase 2Active
Key Facts
About Topadur Pharma
Topadur Pharma is a private, clinical-stage biotech targeting age-related diseases driven by microvascular dysfunction. Its core asset is the DualTOP® platform, which employs a dual mechanism to induce vasodilation and angiogenesis for localized tissue regeneration. The pipeline features two lead programs, TOP-N53 for digital ulcers and diabetic foot ulcers and TOP-M119 for androgenetic alopecia, both advancing through Phase 2. The company follows a capital-efficient, partnership-driven strategy to advance its assets through proof-of-concept trials.
View full company profileTherapeutic Areas
Other Androgenetic Alopecia Drugs
| Drug | Company | Phase |
|---|---|---|
| FOL-005 | Takeda | Phase 2a |
| AMP-303 | Amplifica | Phase 1 |
| GM-502 | Galderma Group | Phase 2 |
| GSK-3β Inhibitor (Topical) | Cosmo Pharmaceuticals | Phase II |